Posts

AbbVie Enters Competitive RAS Oncology Field with $1.45B Biobucks Deal for Kestrel Option

on
AbbVie announced a deal worth up to $1.45 billion in biobucks, including an option to acquire Kestrel Therapeutics, targeting the pan-RAS space in oncology. The agreement allows AbbVie to dip into the 'boiling RAS waters,' a hot area for RAS-driven cancer therapies. This deal was reported on April 28, 2026, amid broader industry interest in RAS inhibitors, separate from buyout rumors involving Revolution Medicines where AbbVie was mentioned but denied involvement. 2 Sources: 2. https://www.biospace.com/business/revolution-soars-amid-swirling-buyout-rumors-with-merck-abbvie

Novartis CEO on Continued Evaluation of In Vivo CAR-T Therapies Without Current Deals

on

FDA Proposes to Withdraw Approval of Amgen's Tavneos Over Data Manipulation and Safety Issues

on

Profluent and Eli Lilly Announce $2.25 Billion Partnership for AI-Designed Genetic Medicines

on

CorMedix and Mundipharma Advance Rezzayo Expansion with Positive Phase III ReSPECT Trial Results

on

Boehringer Ingelheim and Zealand Pharma's Survodutide Matches Wegovy in Weight Loss but Trails Zepbound in Phase 3 Trial

on

Compass Therapeutics Stock Plummets After Mixed Trial Data in Biliary Tract Cancer Study

on

Xpress Wellness Appoints Joe Willey as Chief Operating Officer

on

UC Berkeley Startup Develops Jumping Genes Gene Therapy for Sustained GLP-1 Weight Loss

on

Oruka Therapeutics Announces Strong Phase 2a Results for ORKA-001 in Plaque Psoriasis, Outperforming Skyrizi

on

Erasca and Revolution Medicines Clash Over RAS Patent Infringement for ERAS-0015

on

EKF Diagnostics Holdings Appoints New CFO Helen Jones

on

agilon health Appoints Tim O’Rourke as Chief Executive Officer

on